Safety review record^↗↗Safety records^↗

TB-500^↗↗

Related names in cited records: N-terminal acetylated 17-23 fragment of thymosin beta-4^↗↗

A thymosin beta-4 fragment represented in FDA identity and pharmacy-compounding review records.^↗↗

Citation markers ↗ open the public records supporting the adjacent statements.

Profile update · July 29, 2026

We added FDA's July 2026 pharmacy-compounding review and changed the display status from identity-only to a pending safety review without implying a final FDA determination. ²³

This version supersedes public version 1.

Evidence summary

What the cited records say

FDA's identity record maps TB-500 to a thymosin beta-4 fragment, while FDA's July 2026 briefing addresses its pharmacy-compounding review. Committee recommendations are nonbinding, and FDA's final determination remains pending.^↗↗↗

This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.

Cited context

Related records

Organizations named in cited records

U.S. Food and Drug Administration^↗↗↗

Dated source history

Updates connected to this profile

July 24, 2026
Regulatory
FDA committee met on seven peptide-related groups of bulk drug substances^↗
FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.^↗